India, April 1 -- In a move that could accelerate and reshape therapeutic development, Google DeepMind has launched TxGemma, a suite of open AI models designed to make drug discovery faster, smarter, and more cost-efficient. The announcement was made by Shekoofeh Azizi, Staff Research Scientist, on March 25, 2025.

TxGemma is a collection of lightweight, high-performing open models that are fine-tuned from DeepMind's Gemma 2 architecture. These models are built specifically to assist in therapeutic development, from identifying promising drug targets to predicting outcomes of clinical trials.

With over 7 million therapeutic examples used in training, TxGemma models excel in prediction and conversational analysis, potentially helping rese...